Q-omics provides the consensus-scored PCDH8 profile across patient tissues and cancer cell-line models. PCDH8 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PCDH8 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, PCDH8 RNA expression shows 11,780 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, COAD, and TGCT as cancer lineages where PCDH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH8 survival associations across molecular data types. PCDH8 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH8 RNA expression–survival associations across cancer types. High PCDH8 expression shows unfavorable associations in UCEC, BLCA, KIRP and THCA, but favorable associations in UCS and UVM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for PCDH8 RNA expression.
This table summarizes PCDH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCDH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH8 shows lower tumor expression in COAD, STAD and READ and higher tumor expression in LUSC, THCA and LUAD. The COAD box plot shows higher PCDH8 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with PCDH8 in patient tissues and cancer cell lines. In patient samples, PCDH8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
